Scandinavian CRO acquired by Labquality
Our role
Evli Corporate Finance acted as exclusive financial adviser to Labquality in the acquisition of Scandinavian CRO
Buyer
Labquality
Labquality comprises of a team of experienced experts in healthcare and health-tech quality. The company’s quality services for the healthcare, pharmaceutical and medical technology industries cover external quality assessments, regulatory consulting, clinical investigations and trials, audits and certifications, and training. Labquality’s expertise and knowledge benefit medical device and in vitro diagnostic manufacturers, pharmaceutical companies, healthcare units, and clinical laboratories
Currently, we serve customers in over 60 countries. Our team comprises 150 skilled professionals, and our offices are in Finland, Sweden, Poland, and Germany
Mérieux Equity Partners
Founded in 2009, Mérieux Equity Partners (“MxEP”) is a leading European healthcare-specialized investment firm, with two dedicated platforms, Venture Capital and Buyout, supporting companies ranging from start-ups to established leaders. Benefiting from a longstanding expertise and a large network, MxEP invests in companies with ambitious growth projects and products or services transformative for Health. MxEP is AMF-accredited and currently manages c.€1.5bn of AuM. Labquality has been supported by Mérieux Equity Partners since November 2023
Target
Scandinavian CRO is an established and highly distinguished CRO that specializes in clinical trials services for pharmaceutical, medical device, and in vitro diagnostic device companies. The company has a strong position in the CRO market both in Sweden and in other Scandinavian countries. The acquisition makes Labquality into a full service CRO enabling it to continue geographic expansion and growth
The acquisition aligns with Labquality’s international growth strategy and enables Labquality to grow its business in Sweden and to enter new markets like Norway and Denmark